Seattle, WA – According to filings with the U.S. Securities and Exchange Commission, Sana Biotechnology is raising $45,850,000.00 in new funding. Sources indicate as part of senior management President and Chief Executive Officer, Steven Harr played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Sana Biotechnology

We are deploying a platform that can repair and control genes in cells or replace any cell in the body. Imagine a world in which it is possible to cure genetically inherited diseases and modify genes to create better therapeutics for acquired diseases. Sana’s in vivo Cell Engineering platform aims to provide solutions for patients that current gene therapies cannot address. Success will require creative science, experienced product and clinical development strategies, and aggregating important technologies.

To learn more about Sana Biotechnology, visit http://sana.com/

Contact:
Steven Harr, President and Chief Executive Officer
206-701-7914
steve.harr@sana.com

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved